Also found in: Dictionary, Thesaurus, Wikipedia.


a proton pump inhibitor used to inhibit gastric acid secretion for the treatment of duodenal or gastric ulcer, gastroesophageal reflux disease, or other conditions due to gastric hyperacidity; administered orally.


Prevacid, Prevacid SoluTab, Prevacid 24HR, Zoton (UK)

Pharmacologic class: Gastric acid pump inhibitor

Therapeutic class: Antiulcer drug

Pregnancy risk category B


Inhibits activity of proton pump in gastric parietal cells, decreasing gastric acid production


Capsules (delayed-release): 15 mg, 30 mg

Granules for oral suspension (delayed-release, enteric-coated): 15 mg, 30 mg

Prevpac (combination product for Helicobacter pylori infection): daily pack containing two 30-mg lansoprazole capsules, four 500-mg amoxicillin capsules, and two 500-mg clarithromycin tablets

Prevacid NapraPAC 375 (combination product for reducing risk of ulcers from nonsteroidal anti-inflammatory drugs [NSAIDs]): weekly pack containing seven 15-mg Prevacid capsules and fourteen 375-mg Naprosyn tablets

Prevacid NapraPAC 500 (combination product for reducing risk of ulcers from NSAIDs): weekly pack containing seven 15-mg Prevacid capsules and fourteen 500-mg Naprosyn tablets

Prevacid SoluTab (delayed-release, orally disintegrating tablet): 15 mg, 30 mg

Indications and dosages

Active duodenal ulcer

Adults: 15 mg P.O. daily for 4 weeks

Maintenance of healed duodenal ulcer

Adults: 15 mg P.O. daily

H. pylori eradication, to reduce risk of duodenal ulcer recurrence

Adults: In triple therapy, 30 mg lansoprazole P.O., 1 g amoxicillin P.O., and 500 mg clarithromycin P.O. q 12 hours for 10 or 14 days. In dual therapy, 30 mg lansoprazole P.O. and 1 g amoxicillin P.O. q 8 hours for 14 days.

Benign gastric ulcer

Adults: 30 mg P.O. daily for up to 8 weeks

Gastric ulcer associated with NSAIDs

Adults: 30 mg P.O. once daily for up to 8 weeks

To reduce risk of NSAID-associated gastric ulcer

Adults: 15 mg P.O. daily for up to 12 weeks

Gastroesophageal reflux disease

Adults and children ages 12 to 17: 15 mg P.O. daily for up to 8 weeks

Children ages 1 to 11 weighing more than 30 kg (66 1b): 30 mg P.O. daily for up to 12 weeks

Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks

Erosive esophagitis

Adults and children ages 12 to 17: 30 mg P.O. daily for up to 8 weeks. Some patients may require 8 additional weeks.

Children ages 1 to 11 weighing more than 30 kg (66 lb): 30 mg P.O. daily for up to 12 weeks

Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks

To maintain healing of erosive esophagitis

Adults: 15 mg P.O. daily

Pathologic hypersecretory conditions (including Zollinger-Ellison syndrome)

Adults: Initially, 60 mg P.O. daily, to a maximum of 90 mg P.O. b.i.d. Divide daily dosages over 120 mg.

Frequent heartburn (two or more times a week)

Adults: 15 mg P.O. (delayed-release capsule) daily up to 14 days

Dosage adjustment

• Significant hepatic insufficiency


• Hypersensitivity to drug or its components


Use cautiously in:
• phenylketonuria (orally disintegrating tablets), severe hepatic impairment
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 18.


• Give oral form before meals.
• If patient has difficulty swallowing delayed-release capsule, open it and sprinkle contents onto small amount of soft food, such as applesauce or pudding. Don't crush or let patient chew drug.
• When giving orally disintegrating tablet, place tablet on patient's tongue and let it disintegrate until particles can be swallowed.
• Know that orally disintegrating tablet contains phenylalanine.
• When giving oral suspension, empty packet contents into container with 2 tbsp water. Stir contents well, and have patient drink immediately. Don't give oral suspension through nasogastric (NG) tube.
• When injecting contents of delayed-release capsule through NG tube, open capsule and mix granules with 40 ml apple juice. Then rinse tube with additional apple juice to clear.

Adverse reactions

CNS: headache, confusion, anxiety, malaise, paresthesia, abnormal thinking, depression, dizziness, syncope, cerebrovascular accident

CV: chest pain, hypertension, hypotension, myocardial infarction, shock

EENT: visual field deficits, otitis media, tinnitus, epistaxis

GI: nausea, diarrhea, abdominal pain, cholelithiasis, ulcerative colitis, esophageal ulcer, hematemesis, stomatitis, dysphagia, GI hemorrhage

GU: renal calculi, erectile dysfunction, abnormal menses, breast tenderness, gynecomastia

Hematologic: anemia

Musculoskeletal: hip, wrist, spine fractures (with long-term daily use)

Respiratory: cough, bronchitis, asthma

Skin: urticaria, alopecia, acne, pruritus, photosensitivity


Drug-drug.Drugs requiring acidic pH (such as ampicillin esters, digoxin, iron salts, itraconazole, ketoconazole): decreased absorption of these drugs

Sucralfate: decreased lansoprazole absorption

Theophylline: increased theophylline clearance

Drug-food.Any food: decreased rate and extent of GI drug absorption

Drug-herbs.Male fern: inactivation of herb

St. John's wort: increased risk of photosensitivity

Patient monitoring

• Monitor for GI adverse reactions.
• Assess nutritional status and fluid balance to identify significant problems.

Patient teaching

• Instruct patient to take before meals.
• If patient has difficulty swallowing, tell him to open delayed-release capsule and sprinkle contents onto small amount of soft food (such as applesauce or pudding). Emphasize that he must not crush or chew drug.
• Tell patient to take orally disintegrating tablet by placing it on tongue and letting it disintegrate.
• Instruct patient to take oral suspension by emptying packet contents into container with 2 tbsp water. Tell him to stir contents well and drink immediately.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.


/lan·so·pra·zole/ (lan-so´prah-zōl) a proton pump inhibitor used to inhibit gastric acid secretion for the treatment of duodenal or gastric ulcer, gastroesophageal reflux disease, and hyperchlorhydria.


A drug of the proton pump inhibitor class, C16H14F3N3O2S, used to treat esophagitis caused by gastroesophageal reflux disease and other disorders associated with increased gastric acid secretion.


an antiulcer agent and proton pump inhibitor.
indications It is used to treat gastroesophageal reflux disease (GERD), severe erosive esophagitis, poorly responsive systemic GERD, and pathological hypersecretory conditions (Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas). It is also a potentially effective treatment for duodenal and gastric ulcers and for maintenance of healed duodenal ulcers.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Life-threatening effects are cerebrovascular accident, myocardial infarction, shock, hematuria, and hemolysis. Other adverse effects include confusion, agitation, amnesia, depression, diarrhea, vomiting, nausea, acid regurgitation, anorexia, irritable colon, upper respiratory infections, asthma, bronchitis, dyspnea, alopecia, weight gain or loss, gout, deafness, eye pain, otitis media, chest pain, angina, tachycardia, bradycardia, palpitations, hypertension or hypotension, vasodilation, glycosuria, impotence, kidney calculus, breast enlargement, and anemia.


Prevacid® Therapeutics A proton pump–H+/K+-ATPase inhibitor similar to omeprazole which, with antibiotics–eg, amoxicillin, clarithromycin, and/or metronidazole, is used to eradicate H pylori in Pts with peptic ulcers, erosive esophagitis Adverse effects Diarrhea Contraindications CAD, MI, ASHD


A PROTON PUMP INHIBITOR drug. A brand name is Zoton.

proton pump inhibitors

drugs (e.g. lanzoprazole and omeprazole [Losec]) inhibiting gastric acid secretion (by blocking gastric parietal cell 'proton pump'); used to prevent gastric ulceration in patients on long-term non-steroidal anti-inflammatory drugs


n brand name: Prevacid;
drug class: antisecretory, proton pump inhibitor;
action: suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in gastric parietal cell;
uses: short-term treatment for healing and symptomatic relief of active duodenal ulcer and erosive esophagitis.
References in periodicals archive ?
In one study, 2,624 patients were treated with 40 mg of esomeprazole daily and 2,616 were treated with lansoprazole daffy.
Unlike the new lansoprazole study sponsored by TAP Pharmaceutical Products, the previous studies did not include as end points asthma exacerbations, quality of life, or physician assessment of symptoms, noted Dr.
Lansoprazole and omeprazole are proton pump inhibitors that are commonly used to treat gastrointestinal disorders such as duodenal and gastric ulcers, and gastroesophageal reflux disease.
TAK-390MR combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of drug for extended duration of acid suppression.
The wide confidence interval is probably related to the low rate of events in the lansoprazole group.
In one study, the life table analysis showed that 93 percent and 95 percent of TAK-390MR patients (60 mg and 90 mg, respectively) experienced healing versus 92 percent of lansoprazole 30 mg patients.
The study showed that esomeprazole (NEXIUM) was more effective than lansoprazole in meeting one of the important yardsticks for clinical success - maintaining healing of erosive esophagitis," added Dr.
Our study is the first substantial trial to look at the effect of powerful antacids like lansoprazole, a "proton pump inhibitor", on throat symptoms.
Always got my Claritin, Benadryl, my EpiPen, Lansoprazole, Prevacid.
The lost prescription drugs consist of: Amlodipin, Atenolol, Atorvastatin, Clopidogrel, Cocodamol, Duloxetine, Gyceryl Trinitrate spray, Lansoprazole, Omacor, Perindopril, Erbumine, Pregabalin, Tiotropium inhaler, Tramadol, Ventolin and Zopiclone.
CutisPharma now has twenty four proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, five Magic Mouthwash kits, three omeprazole suspension kits, three lansoprazole suspension kits, and five vancomycin solution kits.
Havas et al evaluated lansoprazole 30 mg in 8 patients and 7 controls for 12 weeks.